Christopher B. Granger

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.8K citations · Full text

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

Renato D. Lópes, John H. Alexander, Sana M. Al‐Khatib et al. · American Heart Journal · 2010 · 455 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +14

Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1fn1This study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.

Brian S. Crenshaw, Samuel R. Ward, Christopher B. Granger et al. · Journal of the American College of Cardiology · 1997 · 399 citations

Thrombosis, Cardiovascular Disease, Medicine +11

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

J. Donald Easton, Renato D. Lópes, M. Cecilia Bahit et al. · The Lancet Neurology · 2012 · 281 citations · Full text

Thrombosis, Aristotle Trial, Ischemic Stroke +12

Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go

Kim A. Eagle, Brahmajee K. Nallamothu, Rajendra H. Mehta et al. · European Heart Journal · 2008 · 269 citations · Full text